PBMs blame insurers for high drug prices

Amy Baxter | | Health Exec | Policy & Regulations

Sky-high drug prices and healthcare costs have quickly turned into a voter issue in Washington, D.C., with politicians promising to go after pharmaceutical companies to lower prices. Pharmacy benefit managers (PBMs)—the industry middlemen that negotiate drug prices—are passing on nearly all their savings to insurance providers, according to Terry Wilcox, co-founder and executive director of advocacy organization Patients Rising. His op-ed for The Hill placed the blame of high costs squarely on insurers.

CVS Health reported it passed on 98 percent of rebates it receives from drug makers to insurers in 2018 disclosures, while Express Scripts passes on 95 percent of rebates to health plan clients and customers. These savings help subsidize premium costs for health plan members, but they also could be bolstering profits for insurers, according to Wilcox.

See the full story below:

Disclosures suggest rebates and insurers responsible for rising out-of-pocket d…

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”